Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Merck Targets Late-2026 Close in Cash Deal for Bio-Techne

Guavy AI Editorial Team
Instruments
MRK
Share

Merck is making a cash acquisition deal for Bio-Techne (NASDAQ: TECH) that targets a completion date of late-2026. This news was revealed in an annual report filed by Bio-Techne with the Securities and Exchange Commission.

The deal's details are not specified in the report, but it mentions that the merger is expected to be completed by the end of 2026. The report also notes that the acquisition will have a significant impact on Bio-Techne's financials, but does not provide further information.

More on Stocks

Stocks just now

Nvidia Reveals Secrets to Building Lasting Corporate Venture Partnerships

Stocks just now

AI Sector Fuels Revenue Surge at Nvidia and Marvell Technology

Stocks 2m ago

IBM Bounces Back from Q2 Software Shortfall with AI-Focused Strategies

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy